Domestic drug companies to keep hot eyes on Amaryl market.

Published: 2003-04-04 06:59:00

Updated: 2003-04-04 06:59:00

The domestic pharmaceutical companies are keenly interests in the Amaryl (glymepiride: a anti-diabetic drug) market since the patent protection already expired in Korea and its post market surveillance (PMS) also ended at coming July this year. Its market size as a single item grew up tremendousl...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK